newsfilter
← Latest News
ACCESS Newswire·

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical